Enlivex Therapeutics (ENLV) investor relations material

Company overview and business model

• Focuses on quality longevity therapies and operates a dual strategy: clinical development in immunotherapy and a treasury model anchored in decentralized prediction markets via the RAIN protocol.

• Clinical-stage company developing Allocetra, an off-the-shelf cell therapy targeting inflammatory conditions, primarily osteoarthritis.

• Treasury operations utilize the RAIN token as the primary reserve asset, providing investor exposure to prediction markets.

• Incorporated in Israel, with principal offices in Ness Ziona and a U.S. subsidiary in Delaware.

Financial performance and metrics

• Entered into a $21.0 million Senior Secured Convertible Promissory Note in March 2026, with $19.0 million received at closing.

• Note matures March 23, 2027, repayable in nine monthly installments of ~$2.3 million, with options for repayment in cash or shares.

• Note can be converted into ordinary shares at an initial price of $40.37625 per share, subject to adjustments.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares; all net proceeds go to the selling shareholder.

• Bears all registration-related fees and expenses for the offering.